{"count": 5, "results": [{"_id": "28507057", "pmid": 28507057, "title": "Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.", "journal": "J Am Soc Nephrol", "authors": ["Stanifer JW", "Charytan DM", "White J", "Lokhnygina Y", "Cannon CP", "Roe MT", "Blazing MA"], "date": "2017-10-01T00:00:00Z", "doi": "10.1681/ASN.2016090957", "meta_date_publication": "2017 Oct", "meta_volume": "28", "meta_issue": "10", "meta_pages": "3034-3043", "score": 50067.543, "text_hl": "The strongest evidence supporting the cardiovascular benefit of statins in individuals with @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@ was shown with @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ plus @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ versus placebo. ", "citations": {"NLM": "Stanifer JW, Charytan DM, White J, Lokhnygina Y, Cannon CP, Roe MT, Blazing MA. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. J Am Soc Nephrol. 2017 Oct;28(10):3034-3043. PMID: 28507057", "BibTeX": "@article{28507057, title={Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.}, author={Stanifer JW and Charytan DM and White J and Lokhnygina Y and Cannon CP and Roe MT and Blazing MA}, journal={J Am Soc Nephrol}, volume={28}, number={10}, pages={3034-3043}}"}}, {"_id": "16490616", "pmid": 16490616, "title": "The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.", "journal": "Am J Kidney Dis", "authors": ["Landray M", "Baigent C", "Leaper C", "Adu D", "Altmann P", "Armitage J", "Ball S", "Baxter A", "Blackwell L", "Cairns HS", "Carr S", "Collins R", "Kourellias K", "Rogerson M", "Scoble JE", "Tomson CR", "Warwick G", "Wheeler DC"], "date": "2006-03-01T00:00:00Z", "doi": "10.1053/j.ajkd.2005.11.018", "meta_date_publication": "2006 Mar", "meta_volume": "47", "meta_issue": "3", "meta_pages": "385-95", "score": 50058.438, "text_hl": "The second United Kingdom Heart @DISEASE_Glycosuria_Renal @DISEASE_MESH:D006030 @@@and Renal@@@ Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ to @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ as initial therapy among @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@.", "citations": {"NLM": "Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, Ball S, Baxter A, Blackwell L, Cairns HS, Carr S, Collins R, Kourellias K, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006 Mar;47(3):385-95. PMID: 16490616", "BibTeX": "@article{16490616, title={The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.}, author={Landray M and Baigent C and Leaper C and Adu D and Altmann P and Armitage J and Ball S and Baxter A and Blackwell L and Cairns HS and Carr S and Collins R and Kourellias K and Rogerson M and Scoble JE and Tomson CR and Warwick G and Wheeler DC}, journal={Am J Kidney Dis}, volume={47}, number={3}, pages={385-95}}"}}, {"_id": "24790178", "pmid": 24790178, "title": "Effects of lowering LDL cholesterol on progression of kidney disease.", "journal": "J Am Soc Nephrol", "authors": ["Haynes R", "Lewis D", "Emberson J", "Reith C", "Agodoa L", "Cass A", "Craig JC", "de Zeeuw D", "Feldt-Rasmussen B", "Fellström B", "Levin A", "Wheeler DC", "Walker R", "Herrington WG", "Baigent C", "Landray MJ", "SHARP Collaborative Group", "SHARP Collaborative Group"], "date": "2014-08-01T00:00:00Z", "doi": "10.1681/ASN.2013090965", "meta_date_publication": "2014 Aug", "meta_volume": "25", "meta_issue": "8", "meta_pages": "1825-33", "score": 50056.984, "text_hl": "Here, 6245 participants with @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@ (not on dialysis) were randomly assigned to @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (20 mg) plus @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ (10 mg) daily or matching placebo. ", "citations": {"NLM": "Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrington WG, Baigent C, Landray MJ, SHARP Collaborative Group, SHARP Collaborative Group. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014 Aug;25(8):1825-33. PMID: 24790178", "BibTeX": "@article{24790178, title={Effects of lowering LDL cholesterol on progression of kidney disease.}, author={Haynes R and Lewis D and Emberson J and Reith C and Agodoa L and Cass A and Craig JC and de Zeeuw D and Feldt-Rasmussen B and Fellström B and Levin A and Wheeler DC and Walker R and Herrington WG and Baigent C and Landray MJ and SHARP Collaborative Group and SHARP Collaborative Group}, journal={J Am Soc Nephrol}, volume={25}, number={8}, pages={1825-33}}"}}, {"_id": "22659373", "pmid": 22659373, "title": "LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.", "journal": "Eur J Pharm Sci", "authors": ["Zinellu A", "Sotgia S", "Pisanu E", "Loriga G", "Deiana L", "Satta AE", "Carru C"], "date": "2012-08-30T00:00:00Z", "doi": "10.1016/j.ejps.2012.05.006", "meta_date_publication": "2012 Aug 30", "meta_volume": "47", "meta_issue": "1", "meta_pages": "117-23", "score": 50054.844, "text_hl": "We enrolled thirty @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@ randomized to receive three different hypolipidemic regimens: @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ alone (40 mg/day) or @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ combined therapy (10/20 or 10/40 mg/day). ", "citations": {"NLM": "Zinellu A, Sotgia S, Pisanu E, Loriga G, Deiana L, Satta AE, Carru C. LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. Eur J Pharm Sci. 2012 Aug 30;47(1):117-23. PMID: 22659373", "BibTeX": "@article{22659373, title={LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.}, author={Zinellu A and Sotgia S and Pisanu E and Loriga G and Deiana L and Satta AE and Carru C}, journal={Eur J Pharm Sci}, volume={47}, number={1}, pages={117-23}}"}}, {"_id": "24626433", "pmid": 24626433, "title": "The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.", "journal": "Clin J Am Soc Nephrol", "authors": ["Herrington W", "Emberson J", "Staplin N", "Blackwell L", "Fellström B", "Walker R", "Levin A", "Hooi LS", "Massy ZA", "Tesar V", "Reith C", "Haynes R", "Baigent C", "Landray MJ", "SHARP Investigators"], "date": "2014-05-01T00:00:00Z", "doi": "10.2215/CJN.10371013", "meta_date_publication": "2014 May", "meta_volume": "9", "meta_issue": "5", "meta_pages": "914-9", "score": 50047.473, "text_hl": "DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Study of Heart and @DISEASE_Glycosuria_Renal @DISEASE_MESH:D006030 @@@Renal@@@ Protection (SHARP) randomized @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@ to 20 mg @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ plus 10 mg @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ daily versus matching placebo. ", "citations": {"NLM": "Herrington W, Emberson J, Staplin N, Blackwell L, Fellström B, Walker R, Levin A, Hooi LS, Massy ZA, Tesar V, Reith C, Haynes R, Baigent C, Landray MJ, SHARP Investigators. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clin J Am Soc Nephrol. 2014 May;9(5):914-9. PMID: 24626433", "BibTeX": "@article{24626433, title={The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.}, author={Herrington W and Emberson J and Staplin N and Blackwell L and Fellström B and Walker R and Levin A and Hooi LS and Massy ZA and Tesar V and Reith C and Haynes R and Baigent C and Landray MJ and SHARP Investigators}, journal={Clin J Am Soc Nephrol}, volume={9}, number={5}, pages={914-9}}"}}]}